<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872570</url>
  </required_header>
  <id_info>
    <org_study_id>MMS.2019.008</org_study_id>
    <nct_id>NCT03872570</nct_id>
  </id_info>
  <brief_title>Effect of Phenylephrine Versus Norepinephrine on Venous Return</brief_title>
  <official_title>Comparison of the Hemodynamic Effects of Phenylephrine and Norepinephrine in Patients Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algemeen Ziekenhuis Maria Middelares</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of general anesthesia often induces a decrease in the mean arterial blood pressure
      (MAP) caused by arterial and venous dilatation. Fluid administration is conventionally used
      to increase the patient's total blood volume, but is often associated with multiple adverse
      events such as postoperative edema.

      Arterial hypotension can also be treated by vasopressor agents such as norepinephrine and
      phenylephrine which mainly increase the blood pressure by arterial vasoconstriction.

      Compared to phenylephrine, norepinephrine has a shorter half-life (2 - 3 minutes) and
      improves the MAP by increase in cardiac contractility. In a recent study at our department it
      was demonstrated that besides arterial vasoconstriction, phenylephrine also improves venous
      return and cardiac output by venous vasoconstriction.

      The aim of this study is to compare the hemodynamic effects of both vasopressor agents in
      patients undergoing deep inferior epigastric perforators (DIEP) flap surgery. If significant
      differences between both agents are demonstrated, these findings can provide an important
      basis for future recommendations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In consecutive patients scheduled for DIEP flap surgery, all hemodynamic and respiratory
      variables are recorded electronically for subsequent off line analysis.

      A systolic blood pressure of minimal 100 mmHg will be maintained during surgery by
      optimization of the cardiac preload and titrated norepinephrine (1.5 µg/kg/h) or
      phenylephrine (15 µg/kg/h) administration. Cardiac preload optimization will be based on
      pulse pressure variation (PPV) measurement, which is calculated by pulse contour analysis of
      the radial arterial pressure curve. Following the international goal-directed fluid therapy
      guidelines, plasmalyte will be administrated if the PPV&gt;11%.

      The tricuspid annular plane systolic excursion (TAPSE) will be measured by transthoracic
      echocardiography (TTE) to evaluate the inotropic effect of norepinephrine and phenylephrine.
      In addition, TTE will be used to measure the cardiac output to calibrate the PPV
      measurements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulse pressure variation</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the pulse pressure variation in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean arterial blood pressure</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the mean arterial blood pressure in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the cardiac output in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke volume (variation)</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the stroke volume (variation) in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the heart rate in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilation frequency</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the ventilation frequency in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>end-tidal CO2</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the end-tidal CO2 in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tidal volume</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the tidal volume in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAPSE</measure>
    <time_frame>perioperative</time_frame>
    <description>the evolution of the tricuspid annular plane systolic excursion in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Arterial Hypotension</condition>
  <arm_group>
    <arm_group_label>phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  patients scheduled for DIEP flap surgery

        Exclusion Criteria:

          -  unwilling or unable to grant written informed consent

          -  contra-indications for phenylephrine or norepinephrine

          -  cardiac arrhythmia

          -  no necessity for pharmacological blood pressure management
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain F Kalmar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maria Middelares Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain F Kalmar, MD, PhD</last_name>
    <phone>+32 246 17 29</phone>
    <email>alain.kalmar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvie Allaert, MD, PhD</last_name>
    <phone>+32 246 17 28</phone>
    <email>silvie.allaert@azmmsj.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain F Kalmar, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Kalmar AF, Allaert S, Pletinckx P, Maes JW, Heerman J, Vos JJ, Struys MMRF, Scheeren TWL. Phenylephrine increases cardiac output by raising cardiac preload in patients with anesthesia induced hypotension. J Clin Monit Comput. 2018 Dec;32(6):969-976. doi: 10.1007/s10877-018-0126-3. Epub 2018 Mar 22.</citation>
    <PMID>29569112</PMID>
  </reference>
  <reference>
    <citation>O'Connell TD, Jensen BC, Baker AJ, Simpson PC. Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev. 2013 Dec 24;66(1):308-33. doi: 10.1124/pr.112.007203. Print 2014. Review.</citation>
    <PMID>24368739</PMID>
  </reference>
  <reference>
    <citation>Beloeil H, Mazoit JX, Benhamou D, Duranteau J. Norepinephrine kinetics and dynamics in septic shock and trauma patients. Br J Anaesth. 2005 Dec;95(6):782-8. Epub 2005 Oct 14.</citation>
    <PMID>16227334</PMID>
  </reference>
  <reference>
    <citation>Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol. 1982;21(4):335-41.</citation>
    <PMID>7056280</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Algemeen Ziekenhuis Maria Middelares</investigator_affiliation>
    <investigator_full_name>Dr. Alain Kalmar, MD, PhD</investigator_full_name>
    <investigator_title>Staff Anesthesist</investigator_title>
  </responsible_party>
  <keyword>cardiac output</keyword>
  <keyword>pulse pressure variation</keyword>
  <keyword>fluid responsiveness</keyword>
  <keyword>hemodynamic monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

